Two groups of patients will be compared: One group of patients with a history of venous thromboembolic disease and one group without. Both groups will be subjected to a walking test and with electrocardiogram measurements and blood tests.
Patients who have given written informed consent.
Patients who are affiliated to or beneficiaries of a social security scheme.
Patients with a personal history of provoked venous thromboembolism, venous thrombosis and/or pulmonary embolism, with the last attack dating back to more than 6 months, and whose clinical phenotype did not justify long-term antithrombotic drug prophylaxis.
First year of combined oestrogen-progestogen oral contraception, or contraception using an oestrogen-impregnated vaginal ring or transcutaneous synthetic oestrogen patch.
Patients who are physically unable to perform the 60-minute walking test, for any reason, in particular cardiovascular contraindications to exercise (recent acute coronary syndrome unstable angina, rhythm disorders, tight aortic stenosis, cardiac heart failure, acute myocarditis, pericarditis or endocarditis endocarditis, poorly controlled hypertension, pre-stress blood pressure > 200/110 mmHg, recent stroke or transient ischemic attack).
Patients on anticoagulant or antithrombotic treatment, ongoing or discontinued within the last month.
Patients treated for pulmonary embolism who remain dyspneic after anticoagulant treatment and requiring a work-up for pulmonary hypertension.
Last surgery dating back to less than 3 months.
Parallel
60-minute walking test
Other interventionTreadmill walking test in the morning, 2 hours after breakfast, following a clinical examination, resting 12-lead electrocardiogram and blood pressure measurement. After a 3-minute warm-up and walking of speed 2.5 km per hour, no incline, the speed and incline are gradually increased to reach a target heart rate close to the theoretical ventilatory threshold, around 70% of the theoretical maximum value (evaluated by Astrand's formula: 220-age), i.e. aerobic conditions of moderate intensity so that prolonged effort can be maintained. Test performed in presence of a physician trained in stress testing. Emergency cart and defibrillator available in the department. Intra-hospital vital emergency protocol in place, with resuscitation teams on standby. The cardiology department, in the same building, can be contacted in the event of a cardiological abnormality during the test or recovery. The test takes 60 minutes, including a 3-minute initial warm-up.
Static blood test
Diagnostic test33.3 ml of blood will be taken from each participant whilst at rest, before undergoing the 60-minute walking test
Post-effort blood test
Diagnostic test33.3 ml of blood will be taken from each participant immediately after undergoing the 60-minute walking test.
Electrocardiogram
Other interventionAn electrocardiogram will be carried out throughout the exercise period and during the first 30 minutes of recovery.
Blood pressure monitoring
Other interventionBlood pressure will be monitored out throughout the exercise period and during the first 30 minutes of recovery.
Thrombin generation dosage before effort in controls
The amount of thrombomodulin in the blood will be measured in nmol/L with the help of Thromboscreen(TM)
Thrombin generation dosage before effort in patients
The amount of thrombomodulin in the blood will be measured in nmol/L with the help of Thromboscreen(TM)
Thrombin generation dosage after effort in controls
The amount of thrombomodulin in the blood will be measured in nmol/L with the help of Thromboscreen(TM). The difference between measurements before and after effort will be measured in nM.min-1
Thrombin generation dosage after effort in patients
The amount of thrombomodulin in the blood will be measured in nmol/L with the help of Thromboscreen(TM). The difference between measurements before and after effort will be measured in nM.min-1
Distribution in the Control group
Measurements in nM.min-1 will be compared to elicit central tendency, dispersion and heterogeneity in the Control group
Distribution in the Patient group
Measurements in nM.min-1 will be compared to elicit central tendency, dispersion and heterogeneity in the Patient group
Thromboscreen test in Controls in the absence of thrombomodulin : Latency time
Latency time in the absence of thrombomodulin will be measured in seconds in Controls.
Thromboscreen test in Controls in the absence of thrombomodulin : Thrombin peak intensity
Thrombin peak intensity in the absence of thrombomodulin will be measured in Controls.
Age in Controls
Ages will be recorded in years
Sex in Controls
Sex will be recorded as Male/Female/Non-binary
Body mass index in Controls
Body mass index of controls will be recorded in units of kg/m²
Age in Patients
Ages will be recorded in years
Click on the lead sponsor to view all of their trials.
